Home  /  Resource Library  /  Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

Results of a phase II study investigating Obinutuzumab for relapsed/refractory chronic lymphocytic leukemia.